BioCardia Seeks Approval in Japan for Cell Therapy for Ischemic Heart Failure
ByAinvest
Monday, Sep 22, 2025 8:08 am ET1min read
BCDA--
BioCardia has had a positive preliminary clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on the CardiAMP Heart Failure Trial results. The agency requested additional details, including clarification on positioning of prespecified composite endpoints and clinical development status in the US. BioCardia is completing responses to their questions and anticipates formal clinical consultation near the end of the year. The company aims to enable access for patients with few therapeutic options who showed significant benefits in the CardiAMP HF study.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet